Patents by Inventor Mario Perkovic

Mario Perkovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240287155
    Abstract: The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin and comprises an open reading frame encoding a chain of a T cell receptor or of an artificial T cell receptor. Such RNA replicons are useful for expressing a T cell receptor or an artificial T cell receptor in a cell, in particular an immune effector cell such as a T cell. Cells engineered to express such T cell receptor or artificial T cell receptor are useful in the treatment of diseases characterized by expression of antigens bound by the T cell receptor or artificial T cell receptor.
    Type: Application
    Filed: December 13, 2023
    Publication date: August 29, 2024
    Inventors: Petra OEHM, Mario PERKOVIC, Ugur SAHIN, Tim BEISSERT
  • Publication number: 20230265454
    Abstract: The present invention embraces an RNA replicon (self-amplifying RNA vector (saRNA)) that can be replicated by a replicase of a self-replicating virus, e.g., a replicase of alphavirus origin. According to the invention, translation of the replicase open reading frame is uncoupled from a 5?-terminal cap by placing translation of the replicase open reading frame under the translational control of an internal ribosome entry site (IRES). Thereby the initiation of translation depends on the molecular properties of the respective IRES, which compared to cap-dependent translation may require less or no cellular initiation factors to direct the ribosome to the translational start site. According to the invention, IRES-controlled replicase translation may allow the use of uncapped synthetic saRNA. Furthermore, the use of an IRES provides for the option to insert additional transgenes upstream to the IRES.
    Type: Application
    Filed: June 1, 2021
    Publication date: August 24, 2023
    Inventors: Mario Perkovic, Sonja Witzel, Tim Beissert, Ugur Sahin
  • Publication number: 20220033852
    Abstract: The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin. The RNA replicon comprises sequence elements required for replication by the replicase, but these sequence elements do not encode any protein or fragment thereof, such as an alphavirus non-structural protein or fragment thereof. Thus, in the RNA replicon according to the invention, sequence elements required for replication by the replicase and protein-coding region(s) are uncoupled. According to the present invention the uncoupling is achieved by the removal of at least one initiation codon compared to a native alphavirus genomic RNA. In particular, the RNA replicon comprises a 5? replication recognition sequence, wherein the 5? replication recognition sequence is characterized in that it comprises the removal of at least one initiation codon compared to a native alphavirus 5? replication recognition sequence.
    Type: Application
    Filed: October 5, 2021
    Publication date: February 3, 2022
    Inventors: Tim Beissert, Ugur Sahin, Mario Perkovic
  • Patent number: 11168337
    Abstract: The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin. The RNA replicon comprises sequence elements required for replication by the replicase, but these sequence elements do not encode any protein or fragment thereof, such as an alphavirus non-structural protein or fragment thereof. Thus, in the RNA replicon according to the invention, sequence elements required for replication by the replicase and protein-coding region(s) are uncoupled. According to the present invention the uncoupling is achieved by the removal of at least one initiation codon compared to a native alphavirus genomic RNA. In particular, the RNA replicon comprises a 5? replication recognition sequence, wherein the 5? replication recognition sequence is characterized in that it comprises the removal of at least one initiation codon compared to a native alphavirus 5? replication recognition sequence.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: November 9, 2021
    Assignees: Moniech RNA Pharmecenticais GmbH, TRON—Translationale Onkologie An Der Universitätsmedizín Der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbH
    Inventors: Tim Beissert, Ugur Sahin, Mario Perkovic
  • Publication number: 20200362313
    Abstract: The present invention describes a virus-derived factor which when provided to cells, e.g., by transfecting the cells with RNA encoding the virus-derived factor, enhances expression of RNA encoding a peptide or protein in the cells. In particular, the virus-derived factor enhances survival of cells, in particular when transfected repetitively with RNA, and reduces an IFN response of cells to transfected RNA. Accordingly, the present invention provides methods and means for enhancing expression of RNA in cells. The cells are preferably transfected with the RNA.
    Type: Application
    Filed: September 11, 2018
    Publication date: November 19, 2020
    Inventors: Marco Alexander Poleganov, Mario Perkovic, Ugur Sahin, Tim Beissert, Andreas Kuhn
  • Publication number: 20200299725
    Abstract: The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin. The RNA replicon comprises sequence elements required for replication by the replicase, but these sequence elements do not encode any protein or fragment thereof, such as an alphavirus non-structural protein or fragment thereof. Thus, in the RNA replicon according to the invention, sequence elements required for replication by the replicase and protein-coding region(s) are uncoupled. According to the present invention the uncoupling is achieved by the removal of at least one initiation codon compared to a native alphavirus genomic RNA. In particular, the RNA replicon comprises a 5? replication recognition sequence, wherein the 5? replication recognition sequence is characterized in that it comprises the removal of at least one initiation codon compared to a native alphavirus 5? replication recognition sequence.
    Type: Application
    Filed: March 13, 2017
    Publication date: September 24, 2020
    Inventors: Tim Beissert, Ugur Sahin, Mario Perkovic
  • Publication number: 20200299724
    Abstract: The present invention generally relates to systems and methods suitable for high-level protein production. While one or more elements of the present invention are derived from an alphavirus, the present invention does not require propagation of virus particles. In particular, a system comprising two separate RNA molecules is foreseen, each comprising a nucleotide sequence derived from an alphavirus: one RNA molecule comprises a RNA construct for expressing alphavirus replicase, and one RNA molecule comprises a RNA re pi icon that can be replicated by the replicase in trans. The RNA construct for expressing alphavirus replicase comprises a 5?-cap. It was surprisingly found that the 5?-cap is suitable for efficiently driving expression of a transgene from the replicon in trans. The system of the present invention enables expression of a protein of interest in a cell or organism, but is not associated with undesired virus-particle formation.
    Type: Application
    Filed: March 13, 2017
    Publication date: September 24, 2020
    Inventors: Tim Beissert, Ugur Sahin, Mario Perkovic
  • Publication number: 20200283497
    Abstract: The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin and comprises an open reading frame encoding a chain of a T cell receptor or of an artificial T cell receptor. Such RNA replicons are useful for expressing a T cell receptor or an artificial T cell receptor in a cell, in particular an immune effector cell such as a T cell. Cells engineered to express such T cell receptor or artificial T cell receptor are useful in the treatment of diseases characterized by expression of antigens bound by the T cell receptor or artificial T cell receptor.
    Type: Application
    Filed: September 12, 2018
    Publication date: September 10, 2020
    Inventors: Petra OEHM, Mario PERKOVIC, Ugur SAHIN, Tim BEISSERT
  • Publication number: 20200277627
    Abstract: The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin and comprises an open reading frame encoding a reprogramming factor. Such RNA replicons are useful for expressing a reprogramming factor in a cell, in particular a somatic cell. Cells engineered to express such reprogramming factors are useful in cell transplantation therapies.
    Type: Application
    Filed: September 11, 2018
    Publication date: September 3, 2020
    Inventors: Marco Alexander POLEGANOV, Mario PERKOVIC, Ugur SAHIN, Tim BEISSERT
  • Publication number: 20110129490
    Abstract: The invention relates to APOBEC4 proteins and N- or C-terminally modified APOBEC4 proteins for the modulation of the release of retroviruses or viral particles thereof from cells and various uses thereof. Expression of APOBEC4 or N-terminally stabilized APOBEC4 protein in a cell leads to an increased viral production, while expression of C-terminally modified APOBEC4 protein leads to a decrease in viral production.
    Type: Application
    Filed: June 26, 2008
    Publication date: June 2, 2011
    Inventors: Mario Perkovic, Carsten Munk, Klaus Cichutek, Daniela Marino